ClinicalTrials.gg
CompletedNCT01072344Updated Jul 6, 2017Results posted

Long Term Chamomile Therapy for Anxiety

A Phase 3 interventional study of Chamomile (Matricaria recutita) in Generalized Anxiety Disorder, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-07-06.

Sponsored by University of Pennsylvania · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
82nd of 234
180 · median 90
Started
2010
with 11 others
Phase 3
45 of 265
6 open now
Registered
85th of 265
by date
Lead sponsor
7 of 265
University of Pennsylvania

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 82nd largest by enrollment of the 234 interventional ones that give a count, is one of 12 that started in 2010, is one of 45 in phase 3, and was the 85th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

Prior research has shown that chamomile may be an effective, short-term anti-anxiety treatment. This study will examine the initial and long-term benefits of chamomile extract therapy for the prevention of recurrent anxiety disorder.

Read the detailed description

Anxiety disorders are among the most common psychiatric conditions. They affect up to 25% of the US adult population. Generalized anxiety disorder (GAD) is a chronic, recurrent form of the disorder. Although benzodiazepines and serotonin reuptake inhibitors have become the mainstay therapy of GAD, these drugs are often associated with unwanted side effects, habituation, and withdrawal symptoms. Many individuals decline using conventional drug therapy for financial, cultural, or personal reasons such as the stigma of mental illness. As a result, many individuals will seek alternative therapy for their anxiety symptoms. The identification of effective alternative therapies for GAD would be of particular relevance. Among alternative therapies for anxiety, chamomile has been used as a traditional herbal medicine for its calming effect. It is well tolerated and demonstrates pharmacological activity in animal models of anxiety. Despite its widespread use and availability, there has been only one clinical trial of chamomile safety and efficacy in GAD. The current application seeks to build upon the results of that prior chamomile study. In that 8-week, double-blind, placebo-controlled trial, we found a significant superiority of chamomile (vs. placebo) in reducing GAD symptoms. We also found chamomile to be exceedingly well tolerated (vs. placebo). The current application seeks to extend these promising preliminary results by conducting a randomized, double-blind, parallel group, placebo-substitution, long-term safety and efficacy study of chamomile in preventing GAD relapse. For specific aim #1 we will ask: "Does long-term chamomile therapy (vs. placebo) prolong the time to relapse of anxiety symptoms following recovery from GAD?" To answer this question, 180 patients with moderate to severe GAD will receive open-label chamomile extract 500-1,500 mg daily for 8 weeks. Responders to chamomile, who remain well for 4 additional weeks of consolidation therapy, will be randomized to double-blind continuation therapy with chamomile 500-1,500 mg daily or placebo for an additional 26 weeks. We hypothesize that continuation chamomile therapy will result in a prolonged time to relapse (vs. placebo). For specific aim #2 we will ask: "What is the relative safety and tolerability of long-term chamomile therapy (vs. placebo) in patients who have recovered from GAD?" To answer this question, we will examine the following outcome measures: (i) the proportion of patients in each treatment condition who relapse; (ii) the frequency, severity, and duration of treatment-emergent adverse events; (iii) the frequency of discontinuation symptoms during initial double-blind therapy; and, (iv) the frequency of early study discontinuation. We hypothesize that chamomile therapy will result in a lower proportion of anxiety relapses and a lower study discontinuation rate (vs. placebo). We further hypothesize that chamomile therapy will result in a similar frequency of discontinuation symptoms and treatment-emergent adverse events (vs. placebo).

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Anxiety
  • Chamomile
  • Herbal Remedy
  • Complementary and Alternative Medicine
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women at least 18 years old (all races and ethnicity)
  • DSM IV diagnosis of GAD as the primary anxiety disorder
  • Baseline GAD-7 score ≥ 10
  • Baseline CGI/S score at least 4
  • Not taking anti-anxiety medication (e.g., Benzodiazepines, buspirone, antidepressants)
  • Not taking antidepressant, mood stabilizer, or tranquilizer therapy for a prior DSM IV Axis I mood disorder that is in remission
  • Able to understand and provide
  • Able to participate in a 38-week study

Exclusion criteria

Exclusion Criteria:

  • Patients \< 18 years old
  • Primary DSM IV Axis I anxiety disorder other than GAD (e.g., panic disorder with or without agoraphobia, phobia disorder, acute stress disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance-induced anxiety disorder)
  • Current DSM IV Axis I psychotic disorder
  • Substance abuse or dependence within the prior 3 months
  • Current DSM IV Axis I bipolar or major depressive disorder [Note: Patients with co-morbid depressive disorder NOS (e.g., minor depression, recurrent brief depressive disorder, or premenstrual dysphoric disorder (PMDD)] will not be excluded
  • Unstable medical condition
  • Allergy to chamomile
  • Documented allergy to plants of the asteraceae family (e.g., ragweed, asters, chrysanthemum)
  • Allergic to mugwort or birch pollen
  • Concurrent anti-anxiety tranquilizer, antidepressant or mood stabilizer therapy
  • Concurrent use of over-the-counter anti-anxiety and/or antidepressant preparations (e.g., chamomile, St. John's Wort, kava kava)
  • Concurrent use of established antidepressant, mood stabilizer, or tranquilizer therapy for pre-existing affective disorder. [Note: Patients with a history of affective disorder (in remission) who are not currently taking antidepressant, mood stabilizer, or tranquilizer therapy are not excluded from the trial]
  • Women of not willing to use a medically proven form of
  • Positive pregnancy test
  • Actively suicidal or suicide attempt within the preceding 12 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Chamomile Extract

    Pharmaceutical grade oral chamomile extract.

    Drug: Chamomile (Matricaria recutita)

  • Placebo comparator
    Placebo

    Pharmaceutical grade lactose monohydrate.

    Drug: Chamomile (Matricaria recutita)

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Relapse in Each Treatment Condition.

    The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).

    Time frame: 26 weeks

Secondary outcomes

  1. The Proportion of Subjects in Each Treatment Condition Who Relapse.

    The proportion of subjects in each treatment condition who relapsed after randomization

    Time frame: 26 weeks

  2. Frequency, Severity, and Duration of Treatment-emergent Adverse Events.

    We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.

    Time frame: 26 weeks

  3. Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.

    Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %

    Time frame: 26 weeks

  4. Frequency of Early Study Discontinuation in Each Treatment Condition.

    This is the # of subjects who discontinued the study during randomization phase due to other reasons.

    Time frame: 26 weeks

07

Results

Posted Jul 6, 2017

Participant flow

Participant flow — Overall Study
MilestoneChamomile ExtractPlacebo
Started4647
Completed3529
Not completed1118
Withdrew: Relasped-reached end point712
Withdrew: Protocol violation12
Withdrew: Lost to follow-up34

Outcome measures

PrimaryTime to Relapse in Each Treatment Condition.

The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).

Time frame:
26 weeks
Reported as:
Mean · weeks
Time to Relapse in Each Treatment Condition.
weeksChamomile ExtractPlacebo
Time to Relapse in Each Treatment Condition.11.4 ± 8.46.3 ± 3.9
SecondaryThe Proportion of Subjects in Each Treatment Condition Who Relapse.

The proportion of subjects in each treatment condition who relapsed after randomization

Time frame:
26 weeks
Reported as:
Count of participants · Participants
The Proportion of Subjects in Each Treatment Condition Who Relapse.
ParticipantsChamomile ExtractPlacebo
The Proportion of Subjects in Each Treatment Condition Who Relapse.712
SecondaryFrequency, Severity, and Duration of Treatment-emergent Adverse Events.

We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Frequency, Severity, and Duration of Treatment-emergent Adverse Events.
ParticipantsChamomile ExtractPlacebo
Frequency, Severity, and Duration of Treatment-emergent Adverse Events.89
SecondaryFrequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.

Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.
ParticipantsChamomile ExtractPlacebo
# of subject had no new symptoms after randomizat3133
# of subject had >=1 new symptom after randomizati1411
SecondaryFrequency of Early Study Discontinuation in Each Treatment Condition.

This is the # of subjects who discontinued the study during randomization phase due to other reasons.

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Frequency of Early Study Discontinuation in Each Treatment Condition.
ParticipantsChamomile ExtractPlacebo
# Lost to Follow-up34
# withdrawn due to non-compliance12

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chamomile Extract—0/46 (0%)8/46 (17.4%)
Placebo—0/47 (0%)9/47 (19.1%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventChamomile ExtractPlacebo
NauseaGastrointestinal disorders3/460/47
Dry mouthGeneral disorders2/460/47
taste perversionProduct Issues1/462/47
BruisingSkin and subcutaneous tissue disorders0/462/47
Decreased platelet countBlood and lymphatic system disorders0/462/47
CongestionRespiratory, thoracic and mediastinal disorders1/461/47
DiarrheaGastrointestinal disorders1/460/47
DizzinessNervous system disorders1/460/47
DrowsinessNervous system disorders1/460/47
FatigueGeneral disorders1/460/47

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Chamomile ExtractPlaceboTotal
<=18 years000
Between 18 and 65 years404282
>=65 years6511
Age, Continuous
Age, Continuous(years)Chamomile ExtractPlaceboTotal
Mean49.2 ± 14.345.4 ± 16.147.3 ± 15.3
Sex: Female, Male
Sex: Female, Male(Participants)Chamomile ExtractPlaceboTotal
Female343165
Male121628
Region of Enrollment
Region of Enrollment(participants)Chamomile ExtractPlaceboTotal
United States464793
08

Study locations

1 site
  • Depression Research Unit
    Philadelphia, Pennsylvania 19104-3309, United States
09

References and documents

Publications

  • Keefe JR, Guo W, Li QS, Amsterdam JD, Mao JJ. An exploratory study of salivary cortisol changes during chamomile extract therapy of moderate to severe generalized anxiety disorder. J Psychiatr Res. 2018 Jan;96:189-195. doi: 10.1016/j.jpsychires.2017.10.011. Epub 2017 Oct 16. PubMed 29080520 ↗
  • Mao JJ, Xie SX, Keefe JR, Soeller I, Li QS, Amsterdam JD. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine. 2016 Dec 15;23(14):1735-1742. doi: 10.1016/j.phymed.2016.10.012. Epub 2016 Oct 24. PubMed 27912875 ↗
  • Keefe JR, Amsterdam J, Li QS, Soeller I, DeRubeis R, Mao JJ. Specific expectancies are associated with symptomatic outcomes and side effect burden in a trial of chamomile extract for generalized anxiety disorder. J Psychiatr Res. 2017 Jan;84:90-97. doi: 10.1016/j.jpsychires.2016.09.029. Epub 2016 Sep 30. PubMed 27716513 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2010
First posted
Feb 22, 2010
Start
Feb 2010
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
Jul 6, 2017
Last update
Jul 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01072344
Responsible party
Sponsor
First posted
Feb 22, 2010
Start date
Feb 2010
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Jul 6, 2017
Last update
Jul 6, 2017

Study contacts

Jun J Mao, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Matricaria recutita

Start the discussion